These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 21369716)

  • 21. Long-Term Survivor with Intrathecal and Intravenous Trastuzumab Treatment in Metastatic Breast Cancer.
    Pluchart H; Jacquet E; Charlety D; Allenet B; Bedouch P; Mousseau M
    Target Oncol; 2016 Oct; 11(5):687-691. PubMed ID: 27041112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
    Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
    Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.
    De Maio E; Pacilio C; Gravina A; Morabito A; Di Rella F; Labonia V; Landi G; Nuzzo F; Rossi E; Silvestro P; Botti G; Di Bonito M; Curcio MP; Formichelli F; La Vecchia F; Staiano M; Maurea N; D'Aiuto G; D'Aiuto M; Thomas R; Signoriello G; Perrone F; de Matteis A
    BMC Cancer; 2007 Mar; 7():50. PubMed ID: 17374151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
    Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
    J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
    Goldenberg MM
    Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma.
    Lai R; Dang CT; Malkin MG; Abrey LE
    Cancer; 2004 Aug; 101(4):810-6. PubMed ID: 15305414
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Constantinidou A; Smith I
    Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
    Modi S; Stopeck A; Linden H; Solit D; Chandarlapaty S; Rosen N; D'Andrea G; Dickler M; Moynahan ME; Sugarman S; Ma W; Patil S; Norton L; Hannah AL; Hudis C
    Clin Cancer Res; 2011 Aug; 17(15):5132-9. PubMed ID: 21558407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A case of breast meningeal carcinomatosis caused by trastuzumab treatment as adjuvant chemotherapy].
    Takahashi H; Fujii T; Inoue Y; Katsura M; Yokoyama G; Matsubayashi Namoto R; Nakayama Y; Momosaki S; Ariyama H; Takenaka M; Otsuka H; Iwakuma N; Toh U; Shirouzu K
    Gan To Kagaku Ryoho; 2010 Aug; 37(8):1607-9. PubMed ID: 20716898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Central nervous system metastases in breast cancer patients administered trastuzumab.
    Duchnowska R; Szczylik C
    Cancer Treat Rev; 2005 Jun; 31(4):312-8. PubMed ID: 15979804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Successful ventilator weaning by trastuzumab in a HER2-positive breast cancer patient with multiple lung metastases].
    Matsuda T; Fujita H; Kunimoto Y; Hosono M; Kimura T; Hayashi T; Maeda T; Yamakawa J; Maeda N; Mizumoto T; Maruyama S; Uenaka Y; Ogino K
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):773-6. PubMed ID: 23863656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
    Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trastuzumab as the lead monoclonal antibody in advanced breast cancer: choosing which patient and when.
    Olver IN
    Future Oncol; 2008 Feb; 4(1):125-31. PubMed ID: 18241007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.
    Pernas S; Gil-Gil M; de Olza MO; Gumà A; Climent F; Petit A; Pla MJ; García-Tejedor A; López-Ojeda A; Falo C; Fernandez-Otega A; Mesia C; Pérez-Martin FJ; Urruticoechea A; Germà JR
    Breast Cancer Res Treat; 2012 Aug; 134(3):1161-8. PubMed ID: 22772380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
    Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
    Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
    Tokuda Y; Suzuki Y; Saito Y; Umemura S
    Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2- overexpressing breast cancer: Case report.
    García FJV; Carrión NP; de la Cruz-Merino L
    Medicine (Baltimore); 2020 Jan; 99(1):e18298. PubMed ID: 31895768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
    Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
    J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.